Organoid Viability
Organoid Viability - Related Videos
03:24
ATP-Based Luciferase Viability Assay: A Homogenous Method to Evaluate the Growth-Inhibitory Potential of Test Agents on Tumor Organoids
0 Views •
2025
In this video, we demonstrate a rapid, single-addition assay to assess cell viability in patient-derived organoids upon treatment with a test agent using intracellular ATP levels as a marker for cellular metabolic activity. The intracellular ATP levels are measured using the luciferase/luciferin reaction, where the emitted light intensity indicates the cellular viability and, in turn, the test agent's growth-inhibitory potency.
03:41
CRC Organoid Culture: A Method to Obtain 3D Organoids from Colorectal Cancer Cells
0 Views •
2023
This video describes the detailed protocol for generating 3D organoids from murine-model derived colorectal cancer cells by propagating them on artificial extracellular matrix coated plates. These CRC organoids can be used as a model to study the primary growth of human tumor cells and metastasis.
04:55
CRC Organoid Cell Labeling: A Method to Generate GFP Lentivirus-transduced Colorectal Cancer Organoid Cells
0 Views •
2023
This video describes the technique of generating CRC organoids transduced by GFP lentiviral particles for enabling fluorescent imaging. These GFP labeled organoids, when placed in animal models, help to study tumor invasion and metastasis.
12:03
Viability Assays for Cells in Culture
0 Views •
Cited by 39 •
2014
Therapeutic compounds are often first examined in vitro with viability assays. Blind cell counts by a human observer can be highly sensitive to small changes in cell number but do not assess function. Computerized viability assays, as described here, can assess both structure and function in an objective manner.
05:47
Counting and Determining the Viability of Cultured Cells
0 Views •
Cited by 19 •
2008
Determining the number of cells in culture is important in standardization of culture conditions and in performing accurate quantitation experiments. In this video, we demonstrate how cells are counted using a hemacytometer.
FAQs
No single measurement captures every aspect of organoid health. Metabolic activity can indicate cellular function, membrane integrity can reveal damaged cells, proliferation reflects continued growth, and morphology shows whether the three-dimensional structure remains intact. Live/dead staining adds a visual measure of surviving and nonviable cells. Combining these readouts gives a more reliable interpretation of experimental effects.
Morphology provides structural context that numerical viability measurements may miss. Changes in three-dimensional organization can indicate loss of tissue integrity even when some cells remain metabolically active. Conversely, preserved structure supports the interpretation that organoids tolerated the culture or treatment conditions. Monitoring morphology alongside cellular measurements helps distinguish broad tissue deterioration from more limited changes in cell activity.
Pre-treatment measurements establish the condition of the organoids before exposure, while post-treatment measurements reveal how chemotherapy, targeted drugs, radiation, or combinations alter that condition. Comparing the two time points helps separate treatment-associated effects from differences already present in culture. This comparison is important when evaluating response patterns, treatment toxicity, and the relative activity of different therapeutic strategies.
Viability assessment combines evidence of continued cellular survival with evidence that the organoid remains responsive under defined conditions. Metabolism, membrane integrity, proliferation, morphology, and live/dead staining can change differently after treatment, so their pattern provides more context than a single endpoint. In cancer models, that pattern helps characterize whether a therapy produces limited, substantial, or structurally disruptive effects.
A basic workflow begins by maintaining organoids under defined culture conditions and recording their initial state. Researchers then apply the experimental treatment, such as a drug, radiation, or combination, and reassess relevant indicators afterward. Measurements may include metabolism, membrane integrity, proliferation, morphology, and live/dead staining. Comparing pre- and post-treatment results supports interpretation of the experimental response.
Researchers can combine metabolic measurements, membrane-integrity assessments, proliferation measurements, morphology observations, and live/dead staining. These approaches provide complementary information about cellular activity, damage, growth, structure, and the proportion of living versus nonviable cells. Selecting several readouts is useful when a treatment affects different aspects of the organoid at different levels, improving confidence in the overall viability assessment.
It is especially useful for drug screening, treatment-response prediction, toxicity evaluation, and developing models that retain features of the originating tumor. Measurements can be used to compare chemotherapy, targeted drugs, radiation, and combination treatments in three-dimensional tissue models. By linking treatment exposure with preserved or impaired organoid condition, viability data supports more physiologically relevant studies for precision oncology.